Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, PURE Bioscience, Inc. reported revenue of $2M, up 12.2% year over year. Operating margin was -103.2% and net margin -108.9%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from PURE's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2M | -103.2% | -108.9% |
| FY2024 | $2M | -162.6% | -170.7% |
| FY2023 | $2M | -210.1% | -211.0% |
| FY2022 | $2M | -201.0% | -188.4% |
| FY2021 | $4M | -58.8% | -59.1% |
How does PURE compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.